Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.

Kobayashi M, Takahashi-Suzuki I, Shimomura T, Iwasawa Y, Hirai H.

Invest New Drugs. 2011 Oct;29(5):921-31. doi: 10.1007/s10637-010-9448-9. Epub 2010 Jun 4.

PMID:
20524038
2.

Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells.

Cho SJ, Kim YJ, Surh YJ, Kim BM, Lee SK.

J Biol Chem. 2011 Jun 3;286(22):19662-71. doi: 10.1074/jbc.M110.209551. Epub 2011 Apr 8.

3.

Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.

Hirai H, Takahashi-Suziki I, Shimomura T, Fukasawa K, Machida T, Takaki T, Kobayashi M, Eguchi T, Oki H, Arai T, Ichikawa K, Hasako S, Kodera T, Kawanishi N, Nakatsuru Y, Kotani H, Iwasawa Y.

Invest New Drugs. 2011 Aug;29(4):534-43. doi: 10.1007/s10637-009-9384-8. Epub 2010 Jan 19.

PMID:
20084424
4.

In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.

Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S, Lal B, Sharma S.

Mol Cancer Ther. 2007 Mar;6(3):918-25.

5.

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.

DePinto W, Chu XJ, Yin X, Smith M, Packman K, Goelzer P, Lovey A, Chen Y, Qian H, Hamid R, Xiang Q, Tovar C, Blain R, Nevins T, Higgins B, Luistro L, Kolinsky K, Felix B, Hussain S, Heimbrook D.

Mol Cancer Ther. 2006 Nov;5(11):2644-58.

6.

BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.

Siemeister G, Lücking U, Wengner AM, Lienau P, Steinke W, Schatz C, Mumberg D, Ziegelbauer K.

Mol Cancer Ther. 2012 Oct;11(10):2265-73. doi: 10.1158/1535-7163.MCT-12-0286. Epub 2012 Jul 19.

8.

Heat-shock-specific phosphorylation and transcriptional activity of RNA polymerase II.

Egyházi E, Ossoinak A, Lee JM, Greenleaf AL, Mäkelä TP, Pigon A.

Exp Cell Res. 1998 Jul 10;242(1):211-21.

PMID:
9665818
9.

cdk-7 Is required for mRNA transcription and cell cycle progression in Caenorhabditis elegans embryos.

Wallenfang MR, Seydoux G.

Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5527-32.

11.

Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.

Natoni A, Murillo LS, Kliszczak AE, Catherwood MA, Montagnoli A, Samali A, O'Dwyer M, Santocanale C.

Mol Cancer Ther. 2011 Sep;10(9):1624-34. doi: 10.1158/1535-7163.MCT-10-1119. Epub 2011 Jul 18.

12.

Binding to DNA of the RNA-polymerase II C-terminal domain allows discrimination between Cdk7 and Cdk9 phosphorylation.

Lolli G.

Nucleic Acids Res. 2009 Mar;37(4):1260-8. doi: 10.1093/nar/gkn1061. Epub 2009 Jan 9.

13.

NF-kappaB and cell-cycle regulation: the cyclin connection.

Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG.

Cytokine Growth Factor Rev. 2001 Mar;12(1):73-90. Review.

PMID:
11312120
14.

Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control.

Oelgeschläger T.

J Cell Physiol. 2002 Feb;190(2):160-9. Review.

PMID:
11807820
16.

Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors.

Jessen BA, Lee L, Koudriakova T, Haines M, Lundgren K, Price S, Nonomiya J, Lewis C, Stevens GJ.

J Appl Toxicol. 2007 Mar-Apr;27(2):133-42.

PMID:
17211896
17.

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.

Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W.

Blood. 2009 May 7;113(19):4637-45. doi: 10.1182/blood-2008-12-190256. Epub 2009 Feb 20.

18.

Evaluating Chemical CDK Inhibitors as Cell Death Inducers.

Hirai H, Nakatsuru Y.

Methods Mol Biol. 2016;1336:167-78. doi: 10.1007/978-1-4939-2926-9_14.

PMID:
26231716
19.
20.

Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.

Caracciolo V, Laurenti G, Romano G, Carnevale V, Cimini AM, Crozier-Fitzgerald C, Gentile Warschauer E, Russo G, Giordano A.

Cell Cycle. 2012 Mar 15;11(6):1202-16. doi: 10.4161/cc.11.6.19663. Epub 2012 Mar 15.

PMID:
22391209

Supplemental Content

Support Center